Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service prostatectomy & nephrectomy cases in Louisiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (203 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 599 | 42% |
| 2020 | 7 | 598 | 45% |
| 2021 | 6 | 629 | 51% |
Robotic radical prostatectomy and laparoscopic nephrectomy. Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Louisiana; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 45 | 2,342−1%/yr | −1%/yr | 5.81.1× | 0% | 2,550 in 2030+1.4%/yr |
| BPH procedures |
Prostatectomy & nephrectomy in every state, and its device makers · Every procedure market in Louisiana · Every state · Compare with Texas
| 2024 |
| 514 |
| 60% |
| 2025 est. | ≈ 520 | – |
| 2026 est. | ≈ 520 | – |
| 2022 | 8 | 683 | 54% |
| 2023 | 5 | 594 | 58% |
| 2024 | 4 | 514 | 60% |
| 2025 from claims | – | 521 422–612 | 61% |
| 2026 forecast | – | 521 408–655 | 62% |
| 2027 forecast | – | 525 389–694 | 63% |
| 2028 forecast | – | 528 374–728 | 63% |
| 2029 forecast | – | 531 361–761 | 64% |
| 2030 forecast | – | 534 349–792 | 65% |
In 2025, 29% inpatient hospital, 71% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~520 | ~150 | ~380 |
| 2027 · ~520 | ~140 | ~380 |
| 2028 · ~530 | ~140 | ~390 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 73% (71% in 2025), inpatient hospital about 27% (29% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 2,467−0.1%/yr |
| −0.1%/yr |
| 1.2 |
| 0% |
| 2,810 in 2030+2.2%/yr |
| North Carolina | 14 | 1,126−2.7%/yr | −2.7%/yr | 1.3 | 0% | 1,310 in 2030+2.6%/yr |
| Georgia | 20 | 1,026−0.3%/yr | −0.3%/yr | 1.3 | 0% | 1,080 in 2030+0.9%/yr |
| Tennessee | 17 | 996−5.4%/yr | −5.4%/yr | 1.6 | 0% | 1,110 in 2030+1.8%/yr |
| Virginia | 21 | 948−2%/yr | −2%/yr | 1.0 | 0% | 1,120 in 2030+2.8%/yr |
| Maryland | 15 | 867−3.9%/yr | −3.9%/yr | 1.0 | 0% | 990 in 2030+2.2%/yr |
| South Carolina | 12 | 808+1.4%/yr | +1.4%/yr | 1.3 | 0% | 1,300 in 2030+8.3%/yr |
| Oklahoma | 10 | 673+0.8%/yr | +0.8%/yr | 1.5 | 0% | 770 in 2030+2.3%/yr |
| Alabama | 5 | 469−7.9%/yr | −7.9%/yr | 1.2 | 0% | 440 in 2030−1.2%/yr |
| Arkansas | 7 | 393−2.1%/yr | −2.1%/yr | 1.1 | 0% | 480 in 2030+3.3%/yr |
| Mississippi | 9 | 389−6.1%/yr | −6.1%/yr | 1.1 | 0% | 330 in 2030−2.7%/yr |
| Kentucky | 5 | 358−1.2%/yr | −1.2%/yr | 0.9 | 0% | 390 in 2030+1.4%/yr |
| District of Columbia | 8 | 277+5.5%/yr | +5.5%/yr | 4.7 | 0% | 380 in 2030+5.5%/yr |
| West Virginia | 1 | 137+2.2%/yr | +2.2%/yr | 0.7 | 0% | 260 in 2030+11%/yr |
| Delaware | 1 | 105−3.9%/yr | −3.9%/yr | 0.6 | 0% | 90 in 2030−3.1%/yr |
| 22 |
| 1,850−5.9%/yr |
| −5.9%/yr |
| 4.50.9× |
| 30% |
| 1,540 in 2030−3.1%/yr |
| Incontinence, prolapse & sacral neuromodulation | 10 | 866−4%/yr | −4%/yr | 2.10.8× | 3% | 710 in 2030−3.3%/yr |
| Hysterectomy, hysteroscopy & ablation | 4 | 800−6.4%/yr | −6.4%/yr | 2.20.8× | 14% | 710 in 2030−2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Intuitive Surgical leads with 98% of company spending on these surgeons in 2025, −1 pts on 2024.
In 2025, 3 companies reported engagement with Louisiana’s surgeons worth $91K in consulting, speaking, meals and travel tied to these products, about $23K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.